|
1.
|
|
8 p, 2.9 MB |
Antagonism of miR-148a attenuates atherosclerosis progression in APOBTGApobec-/-Ldlr+/- mice : A brief report
/
Rotllan, Noemi (Institut d'Investigació Biomèdica Sant Pau) ;
Zhang, X. (Yale University School of Medicine) ;
Canfrán-Duque, A. (Yale University School of Medicine) ;
Goedeke, L. (Yale University School of Medicine) ;
Griñán, Raquel (Institut d'Investigació Biomèdica Sant Pau) ;
Ramírez, C.M. (IMDEA Research Institute of Food and Health Sciences) ;
Suárez, Y. (Yale University School of Medicine) ;
Fernández-Hernando, C. (Yale University School of Medicine) ;
Universitat Autònoma de Barcelona
miR-148a-3p (miR-148a) is a hepatic and immune-enriched microRNA (miRNA) that regulates macrophage-related lipoprotein metabolism, cholesterol homeostasis, and inflammation. The contribution of miR-148a-3p to the progression of atherosclerosis is unknown. [...]
2022 -  10.1016/j.biopha.2022.113419
Biomedicine & pharmacotherapy, Vol. 153 (september 2022) , p. 113419
|
|
|
2.
|
|
|
3.
|
|
7 p, 1.6 MB |
Case report : Identification of a novel variant p.Gly215Arg in the CHN1 gene causing Moebius syndrome
/
Manso-Bazús, Carmen (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Spataro, Nino (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Gabau, Elisabeth (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Beltrán-Salazar, Viviana P. (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Trujillo-Quintero, Juan Pablo (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Capdevila, Núria (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Brunet Vega, Anna (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Baena Díez, Neus (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Jeyaprakash, A Arockia (Ludwig Maximilian Universität) ;
Martinez-Glez, Víctor (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Ruiz, Anna (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Universitat Autònoma de Barcelona
Background: Moebius Syndrome (MBS) is a rare congenital neurological disorder characterized by paralysis of facial nerves, impairment of ocular abduction and other variable abnormalities. MBS has been attributed to both environmental and genetic factors as potential causes. [...]
2024 - 10.3389/fgene.2024.1291063
Frontiers in genetics, Vol. 15 (january 2024)
|
|
|
4.
|
|
11 p, 810.8 KB |
Precision medicine in acute respiratory distress syndrome : workshop report and recommendations for future research
/
Bos, Lieuwe D (University of Amsterdam) ;
Artigas Raventós, Antoni (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Constantin, Jean-Michel (Sorbonne University) ;
Hagens, Laura A. (University of Amsterdam) ;
Heijnen, Nanon (University of Maastricht) ;
Laffey, John (University Hospital Galway) ;
Meyer, Nuala (University of Pennsylvania Perelman School of Medicine) ;
Papazian, Laurent (North hospital - Aix-Marseille University) ;
Pisani, Lara (Policlinico S.Orsola-Malpighi) ;
Schultz, Marcus J. (University of Amsterdam) ;
Shankar-Hari, Manu (Kings College London) ;
Smit, Marry R. (University of Amsterdam) ;
Summers, Charlotte (University of Cambridge) ;
Ware, Lorraine B. (Vanderbilt University Medical Center) ;
Scala, Raffaele (S. Donato Hospital) ;
Calfee, Carolyn S. (University of California) ;
Universitat Autònoma de Barcelona
Acute respiratory distress syndrome (ARDS) is a devastating critical illness that can be triggered by a wide range of insults and remains associated with a high mortality of around 40%. The search for targeted treatment for ARDS has been disappointing, possibly due to the enormous heterogeneity within the syndrome. [...]
2021 - 10.1183/16000617.0317-2020
European Respiratory Review, Vol. 30 (february 2021)
|
|
|
5.
|
|
|
6.
|
|
13 p, 1.2 MB |
Harmonizing Definitions for Diagnostic Criteria and Prognostic Assessment of Transplantation-Associated Thrombotic Microangiopathy : A Report on Behalf of the European Society for Blood and Marrow Transplantation, American Society for Transplantation and Cellular Therapy, Asia-Pacific Blood and Marrow Transplantation Group, and Center for International Blood and Marrow Transplant Research
/
Schoettler, M.L. (Children's Healthcare of Atlanta) ;
Carreras, Enric (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Cho, Byung-Sik (The Catholic University of Korea) ;
Dandoy, Christopher E. (Cincinnati Children's Hospital Medical Center) ;
Ho, Vincent Trien Vinh (Dana-Farber Cancer Institute (Estats Units d'Amèrica)) ;
Jodele, Sonata (Cincinnati Children's Hospital Medical Center) ;
Moissev, I. (Pavlov First Saint Petersburg State Medical University) ;
Sańchez Ortega, Isabel (European Society for Bone Marrow Transplant) ;
Srivastava, Alok (Christian Medical College Vellore) ;
Atsuta, Yoshiko (Aichi Medical University) ;
Carpenter, Paul A. (Seattle Children's Hospital) ;
Koreth, John (Dana-Farber Cancer Institute (Estats Units d'Amèrica)) ;
Kröger, Nicolaus M. (Ohio State. University) ;
Ljungman, Per (Karolinska Institutet (Estocolm, Suècia)) ;
Page, Kristin M. (Medical College of Wisconsin) ;
Popat, Uday R. (The University of Texas MD Anderson Cancer Center) ;
Shaw, Bronwen E. (Medical College of Wisconsin) ;
Sureda Balari, Anna Maria (Institut Catala d'Oncologia-Hospital Duran i Reynals) ;
Soiffer, Robert J. (Dana-Farber Cancer Institute (Estats Units d'Amèrica)) ;
Vasu, Sumithira V. (Ohio State. University)
Transplantation-associated thrombotic microangiopathy (TA-TMA) is an increasingly recognized complication of hematopoietic cell transplantation (HCT) associated with significant morbidity and mortality. [...]
2023 - 10.1016/j.jtct.2022.11.015
Transplantation and Cellular Therapy, Vol. 29 Núm. 3 (march 2023) , p. 151-163
|
|
|
7.
|
|
12 p, 804.5 KB |
RIC versus MAC UCBT in adults with AML : A report from Eurocord, the ALWP and the CTIWP of the EBMT
/
Baron, Frédéric (University of Liege) ;
Ruggeri, Annalisa (Hôpital Saint-Antoine (Paris, França)) ;
Beohou, Eric (Hôpital Saint-Antoine (Paris, França)) ;
Labopin, Myriam (Hôpital Saint-Antoine (Paris, França)) ;
Sanz, Guillermo (Hospital Universitari i Politècnic La Fe (València)) ;
Milpied, Noel (University of Bordeaux) ;
Michallet, Mauricette (Centre Hospitalier de Lyon Sud) ;
Bacigalupo, Andrea (Ospedale San Martino) ;
Blaise, Didier (Aix-Marseille Université) ;
Malouf Sierra, Jorge 1971- (Institut d'Investigació Biomèdica Sant Pau) ;
Socié, Gérard (Hospital Saint-Louis) ;
Cornelissen, Jan J. (Erasmus Medical Center-Daniel den Hoed Cancer Center) ;
Schmid, Christoph (University of Munich) ;
Giebel, Sebastian (Gliwice Branch) ;
Gorin, Norbert-Claude (Hospital Saint Antoine) ;
Esteve, Jordi (Hematology. Hospital Clinic) ;
Ciceri, Fabio (Ospedale San Raffaele) ;
Savani, Bipin N. (Vanderbilt University Medical Center) ;
Mohty, Mohamad (UMRs 938) ;
Gluckman, Eliane (Centre Scientifique de Monaco) ;
Nagler, Arnon (The Chaim Sheba Medical Center) ;
Universitat Autònoma de Barcelona
Nonrelapse mortality (NRM) is the first cause of treatment failure after unrelated cord blood transplantation (UCBT) following myeloablative conditioning (MAC). In the last decade, reduced-intensity conditioning (RIC) regimens have been developed with the aim of reducing NRM and allowing older patients and those with medical comorbidities to benefit from UCBT. [...]
2016 - 10.18632/oncotarget.9599
Oncotarget, Vol. 7 Núm. 28 (2016) , p. 43027-43038
|
|
|
8.
|
|
8 p, 509.4 KB |
GEIS-21 : A multicentric phase II study of intensive chemotherapy including gemcitabine and docetaxel for the treatment of Ewing sarcoma of children and adults: A report from the Spanish sarcoma group (GEIS)
/
Mora, J. (Hospital Sant Joan de Déu (Barcelona, Catalunya)) ;
Castañeda, A. (Hospital Sant Joan de Déu (Barcelona, Catalunya)) ;
Perez-Jaume, S. (Hospital Sant Joan de Déu (Barcelona, Catalunya)) ;
López Pousa, Antonio (Institut d'Investigació Biomèdica Sant Pau) ;
Maradiegue, E. (Hospital Sant Joan de Déu (Barcelona, Catalunya)) ;
Valverde, C. (Hospital Universitari Vall d'Hebron) ;
Martin-Broto, J. (Universidad de Sevilla) ;
Garcia Del Muro, X. (Hospital Universitari de Bellvitge) ;
Cruz, O. (Hospital Sant Joan de Déu (Barcelona, Catalunya)) ;
Cruz, J. (Hospital Universitario de Canarias (La Laguna)) ;
Martinez-Trufero, J. (Hospital Universitario Miguel Servet (Saragossa)) ;
Maurel, J. (Hospital Clínic i Provincial de Barcelona) ;
Vaz, M.A. (Hospital Ramón y Cajal) ;
De Alava, E. (Universidad de Sevilla) ;
De Torres, C. (Hospital Sant Joan de Déu (Barcelona, Catalunya)) ;
Universitat Autònoma de Barcelona
First Spanish trial of Ewing sarcoma (ES) including adults and children with the aim to test the efficacy of Gemcitabine and Docetaxel (G/D) in newly diagnosed high-risk (HR) patients. This was a prospective, multicentric, non-randomised, open study for patients 1/240 years with newly diagnosed ES. [...]
2017 - 10.1038/bjc.2017.252
British Journal of Cancer, Vol. 117 Núm. 6 (may 2017) , p. 767-774
|
|
|
9.
|
|
|
10.
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
